Teknova reported robust financial performance in Q3 2025, with a 9% year-over-year revenue growth driven primarily by strong sales in its Lab Essentials segment, indicating sustained operational excellence.

• Revenue reached $10.5 million, up from $9.6 million in Q3 2024, marking the fifth consecutive quarter of growth.
• Lab Essentials revenue grew 16% to $8.3 million, reflecting a healthy increase in average revenue per customer.
• Clinical Solutions revenue decreased 13% to $1.7 million due to lower average revenue per customer, although customer count increased.
• Operational enhancements are underway, anticipated to improve efficiency and scale revenue to over $200 million by 2026 without significant capex.
• Continued focus on expanding the Clinical Solutions customer base expected to drive long-term growth through to 2026 and beyond.